ResMed (NYSE: RMD) reported Q4 EPS of $2.08, in-line with the analyst estimate of $2.08. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.22 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.